Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033069 · ClinicalTrials.gov registry record · Phase 2
A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 336
- Enrollment target
NCT03033069 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 336 participants.
The verdict
NCT03033069, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 336 participants
- Enrollment target
Study Summary
To evaluate the safety, efficacy and tolerability of brexpiprazole (with placebo) as monotherapy or combination therapy with Zoloft (sertraline) in adults with PTSD.
Interventions
- DRUG Sertraline
- DRUG Brexpiprazole
- DRUG Brexpiprazole Matching Placebo
- DRUG Sertraline Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2017-01-26 |
| Est. Completion | 2018-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033069
The ClinicalTrials.gov registry entry for NCT03033069 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sertraline is the first listed.
NCT03033069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03033069 about?
NCT03033069 is a clinical study titled "A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)". To evaluate the safety, efficacy and tolerability of brexpiprazole (with placebo) as monotherapy or combination therapy with Zoloft (sertraline) in adults with PTSD.
What is the current status of trial NCT03033069?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 336 participants. The study started on 2017-01-26. Estimated completion is 2018-11-12.
What interventions are being tested in trial NCT03033069?
The interventions under investigation include: Sertraline (DRUG), Brexpiprazole (DRUG), Brexpiprazole Matching Placebo (DRUG), Sertraline Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT03033069?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.